Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability
Currently, there are four monoclonal antibodies (mAbs) that target the cluster of
differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab …
differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab …
B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease
HC Wu, GY Gombolay, JH Yang, JS Graves… - Current Neurology and …, 2024 - Springer
B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease | Current Neurology and
Neuroscience Reports Skip to main content SpringerLink Account Menu Find a journal Publish …
Neuroscience Reports Skip to main content SpringerLink Account Menu Find a journal Publish …
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 …
A Elgenidy, NN Abdelhalim, MAM Al-Kurdi… - Frontiers in …, 2024 - frontiersin.org
Background Recent years have seen the emergence of disease-modifying therapies in
multiple sclerosis (MS), such as anti-cluster of differentiation 20 (anti-CD20) monoclonal …
multiple sclerosis (MS), such as anti-cluster of differentiation 20 (anti-CD20) monoclonal …
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study
S Hallberg, B Evertsson, E Lillvall… - European Journal of …, 2024 - Wiley Online Library
Background and purpose Mechanisms behind hypogammaglobulinaemia during rituximab
treatment are poorly understood. Methods In this register‐based multi‐centre retrospective …
treatment are poorly understood. Methods In this register‐based multi‐centre retrospective …
Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience
M Nasello, V Zancan, V Rinaldi, A Marrone… - International Journal of …, 2024 - mdpi.com
Ocrelizumab (OCR), an anti-CD20 monoclonal antibody, is approved for treating relapsing
remitting (RR) and primary progressive (PP) multiple sclerosis (MS). The standard interval …
remitting (RR) and primary progressive (PP) multiple sclerosis (MS). The standard interval …
A personalized approach for anti-CD20 therapies in multiple sclerosis
L Hogenboom, ZLE van Kempen, T Kalincik… - Multiple Sclerosis and …, 2024 - Elsevier
B-cell depleting therapies are frequently used as high efficacy treatments for multiple
sclerosis (MS). We will elaborate on current data and future perspectives of one of the most …
sclerosis (MS). We will elaborate on current data and future perspectives of one of the most …
In search of lost disease: Clinical, qualitative and imaging studies to investigate long-term effects of autologous haematopoietic stem cell transplantation for multiple …
A Tolf - 2023 - diva-portal.org
Objectives: To determine whether treatment with autologous hematopoietic stem cell
transplantation (HSCT) can induce sustained complete remission in patients with multiple …
transplantation (HSCT) can induce sustained complete remission in patients with multiple …